UNICHEMLAB - Unichem Labs.
📢 Recent Corporate Announcements
Unichem Laboratories has issued a postal ballot notice seeking shareholder approval for significant related party transactions (RPTs) for the 2026-27 fiscal year. The company is proposing a ₹1,600 crore limit for transactions with its US subsidiary and a ₹400 crore limit for transactions between its holding company, Ipca Laboratories, and the US subsidiary. Additionally, the company seeks to appoint Dr. Swati Patankar as a Non-Executive Independent Director for a five-year term. These approvals are essential for the company's continued operational integration with its parent and international subsidiaries.
- Proposed ₹1,600 crore limit for material related party transactions between Unichem and its US subsidiary for FY 2026-27.
- Proposed ₹400 crore limit for transactions between holding company Ipca Laboratories and Unichem USA.
- Appointment of Dr. Swati Patankar as a Non-Executive Independent Director for a 5-year term effective February 5, 2026.
- E-voting period scheduled from February 26, 2026, to March 27, 2026.
- Transactions include sale/purchase of goods, contract manufacturing, and product development charges at arm's length.
Unichem Laboratories has received a tax order from the Deputy Commissioner of State Tax, Mumbai, regarding the disallowance of Input Tax Credit (ITC) for FY 2018-19. The demand arises from a vendor's failure to deposit GST into the government treasury, leading to a total liability of ₹1.01 crore including interest and penalties. The company maintains that this order will not have a material impact on its financial or operational activities. Based on legal advice, Unichem plans to file an appeal against the order within the prescribed timelines.
- Total tax demand of ₹1,01,12,080 including interest and penalty.
- ITC of ₹49,35,330 disallowed for FY 2018-19 due to vendor non-compliance.
- Order issued by Deputy Commissioner of State Tax, Appeals, Bandra Division, Mumbai.
- Company intends to challenge the order through a formal appeal process.
- Management confirms no material impact on current operations or financials.
Unichem Laboratories reported a significant jump in consolidated PAT to ₹264.29 crore for Q3 FY26, largely driven by a one-time exceptional gain of ₹275.52 crore from the sale of land and buildings. Revenue from operations remained relatively flat with a slight 2.2% YoY decline to ₹521.17 crore. The company successfully settled a long-standing European Commission fine, recording a related interest expense of ₹58.26 crore as an exceptional item during the nine-month period. Additionally, the board has strengthened its technical leadership by appointing Dr. Swati Patankar, an IIT Bombay professor with 35+ years of R&D experience, as an Independent Director.
- Consolidated PAT rose to ₹264.29 crore in Q3 FY26 from ₹57.85 crore YoY, primarily due to a ₹275.52 crore gain on disposal of assets.
- Revenue from operations stood at ₹521.17 crore for the quarter, compared to ₹533.09 crore in the previous year's corresponding quarter.
- Exceptional items for the nine-month period include a ₹58.26 crore interest charge for the settlement of a Euro 19.55 million EU fine.
- Dr. Swati Patankar appointed as Non-Executive Independent Director for a 5-year term, bringing expertise in drug discovery and molecular microbiology.
- Basic Earnings Per Share (EPS) for the quarter increased to ₹37.54 from ₹8.22 in the previous year.
Unichem Laboratories reported a massive surge in consolidated Net Profit to ₹264.29 crore for Q3 FY26, primarily driven by a one-time exceptional gain of ₹275.52 crore from the sale of its former registered office land and building. However, core operational performance was weak, with revenue from operations declining 2.2% YoY to ₹521.17 crore and profit before exceptional items falling sharply to ₹17.91 crore from ₹61.85 crore YoY. The company also fully settled a long-standing European Commission fine of Euro 19.55 million during the period. Additionally, the board has been reconstituted with the appointment of Dr. Swati Patankar as an Independent Director to bolster technical and R&D expertise.
- Consolidated Net Profit jumped to ₹264.29 Cr, heavily aided by a ₹275.52 Cr exceptional gain from land and building disposal.
- Revenue from operations fell 2.2% YoY to ₹521.17 Cr and declined 10% on a sequential (QoQ) basis.
- Profit before exceptional items and tax dropped significantly to ₹17.91 Cr compared to ₹61.85 Cr in the same quarter last year.
- Settled European Commission fine and interest totaling Euro 19.55 million, with interest costs of ₹58.26 Cr recognized in the nine-month period.
- Appointed Dr. Swati Patankar, a Professor at IIT Bombay, as a Non-Executive Independent Director for a 5-year term.
The USFDA conducted an inspection at Unichem Laboratories' Kolhapur API facility from January 27 to February 2, 2026. The inspection concluded with five observations, which the company has characterized as procedural changes rather than critical failures. Importantly, the company confirmed that none of the observations pertain to data integrity, a common area of concern for regulators. Unichem is required to submit its formal response to the USFDA within 15 days to address these points.
- USFDA inspection conducted at Kolhapur API facility between Jan 27 and Feb 2, 2026
- Inspection concluded with 5 observations related to procedural changes
- Zero observations related to data integrity, reducing the risk of severe regulatory action
- Company committed to providing a formal response to the USFDA within 15 days
Unichem Laboratories' US subsidiary has initiated a voluntary recall of two pharmaceutical products in the United States. The recall affects Doxazosin Tablets (4 mg) due to appearance defects and Bisoprolol Fumarate/Hydrochlorothiazide Tablets (2.5 mg/6.25 mg) for exceeding N-Nitroso Bisoprolol impurity limits. While no adverse events have been reported to date, the recall highlights potential quality control challenges in the US supply chain. Investors should monitor for any subsequent US FDA actions or financial impact from these recalls.
- Voluntary recall of Doxazosin Tablets (4 mg, 1000 count) due to incorrect debossing on some tablets.
- Recall of Bisoprolol Fumarate and Hydrochlorothiazide Tablets (2.5 mg/6.25 mg) for exceeding N-Nitroso Bisoprolol impurity limits.
- The recall was initiated by the company's wholly-owned subsidiary, Unichem Pharmaceuticals (USA), Inc.
- No adverse events related to these recalls have been reported as of January 27, 2026.
Unichem Laboratories has submitted its final report regarding the re-lodgement of transfer requests for physical shares to the stock exchanges. This filing is in compliance with the SEBI circular dated July 2, 2025, and covers the period from December 1, 2025, to January 6, 2026. The report was prepared by the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This is a standard administrative update and does not affect the company's business operations or financial health.
- Compliance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97
- Covers re-lodgement requests from December 1, 2025, to January 6, 2026
- Report prepared by Registrar and Share Transfer Agent, MUFG Intime India Private Limited
- Final report dated January 21, 2026, submitted to BSE and NSE on January 27, 2026
Unichem Laboratories has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The certificate, issued by MUFG Intime India Pvt. Ltd., confirms that all share certificates received for dematerialization were processed and cancelled within the required timelines. This filing ensures that the company's shareholding records are accurately maintained in electronic form. Such filings are mandatory and indicate standard administrative adherence to regulatory requirements.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Issued by MUFG Intime India Pvt. Ltd., the company's Registrar and Share Transfer Agent.
- Confirms that dematerialized securities are listed on the relevant stock exchanges.
- Verification and cancellation of physical certificates completed within prescribed timelines.
Unichem Laboratories has submitted its 5th monthly report regarding the re-lodgement of transfer requests for physical shares for the period ended November 30, 2025. This filing is a mandatory compliance requirement under the SEBI circular dated July 2, 2025. The report was prepared by the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This is a standard administrative disclosure and does not reflect any change in the company's business fundamentals or financial health.
- Submission of the 5th report on physical share transfer re-lodgements for November 2025
- Compliance with SEBI Circular SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97
- Report provided by Registrar and Share Transfer Agent MUFG Intime India Private Limited
- Filing is part of ongoing regulatory requirements for listed entities
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 18.3% YoY to INR 2,110.97 Cr in FY2025. On a standalone basis, Formulations revenue grew 22.2% to INR 1,527.63 Cr, while APIs & Intermediates grew 13.3% to INR 161.17 Cr.
Geographic Revenue Split
Exports dominate operations, accounting for 98.02% of sales revenue. The US market is the primary driver, with Unichem USA contributing 64% of total sales revenue. Regulated markets historically represent 40% of revenue, while India business was 56% in older cycles but has shifted heavily toward exports.
Profitability Margins
Gross profit margin at the consolidated level for FY2025 improved by 0.6% YoY due to yield improvements and better product mix. The company achieved a Profit After Tax (PAT) of INR 137.52 Cr in FY2025, a significant recovery from a loss of INR 93.76 Cr in FY2024.
EBITDA Margin
EBITDA margins have shown recovery from 4.4% in H1 FY2024. Historical standalone margins were approximately 9.8% to 11.5%. The improvement is driven by operational ramp-up at the Ghaziabad and Goa facilities and cost-reduction initiatives in manufacturing.
Capital Expenditure
Capital expenditure for FY2025 was INR 126.31 Cr. The company previously incurred a cumulative capex of INR 857 Cr between FY2020 and FY2023 to enhance manufacturing capacities and R&D capabilities.
Credit Rating & Borrowing
Credit rating was upgraded to [ICRA]A+ (Stable) from [ICRA]A (Stable) in February 2025. Borrowing includes an ECB loan of $6 million for capex and a term loan of INR 125 Cr. Total rated facilities stand at INR 180 Cr.
Operational Drivers
Raw Materials
Active Pharmaceutical Ingredients (APIs) and intermediates are the primary raw materials, with a significant portion produced in-house for captive consumption to ensure supply chain reliability.
Import Sources
Not disclosed in available documents; however, the company emphasizes reduced reliance on external suppliers through backward integration.
Capacity Expansion
Recent expansions include the Ghaziabad plant (launched FY2023) and Unit 2 at Goa. The company is focused on scaling up these facilities to improve fixed overhead absorption.
Raw Material Costs
Raw material costs are managed through yield improvements and backward integration. Standalone revenue from operations increased 20.4% to INR 1,735.70 Cr, supported by margin resilience in input costs.
Manufacturing Efficiency
Efficiency is driven by operational ramp-up at new facilities. Operating cash flow turned positive at INR 72.29 Cr in FY2025 from negative INR 41.57 Cr in FY2024 due to better capacity utilization.
Logistics & Distribution
Not disclosed as a specific percentage of revenue, but elevated freight costs were noted as a factor that subdued profitability in H1 FY2024.
Strategic Growth
Expected Growth Rate
18.30%
Growth Strategy
Growth will be achieved through synergies with the Ipca group, leveraging their distribution network and capacities. Key drivers include the commercialization of newly approved ANDAs in the US, expansion of the CMO (Contract Manufacturing) business, and cost optimization through backward integration.
Products & Services
Generic pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs), and intermediates. Key therapeutic areas include chronic and acute care.
Brand Portfolio
The company has 4 brands in the top 300 (AWACS), with 23 brands generating over INR 10 Cr in revenue and 21 brands over INR 5 Cr.
New Products/Services
Timely commercialization of newly approved ANDAs (Abbreviated New Drug Applications) is expected to be a primary revenue contributor.
Market Expansion
Focus on strengthening strategic presence in the US and other international markets, which already account for 98.02% of standalone sales.
Market Share & Ranking
Ranked 25th in the Indian Domestic Formulations market (as of 2017 data) and holds the No. 1 position in 19 therapeutic sub-groups.
Strategic Alliances
Acquisition of rights and interest in Bayshore Pharmaceuticals LLC, USA, from Ipca Laboratories (holding company) to enhance US market presence.
External Factors
Industry Trends
The pharmaceutical industry is seeing increased consolidation and regulatory scrutiny. Unichem is positioning itself by integrating with Ipca Laboratories to achieve better scale economics and supply reliability.
Competitive Landscape
Faces intense competition from both Indian and international generic pharmaceutical players, leading to persistent pricing pressure.
Competitive Moat
The moat is built on a clean USFDA compliance track record, deep backward integration into APIs (reducing external dependency), and a strong portfolio of 46 therapeutic sub-groups where brands rank in the top 5.
Macro Economic Sensitivity
Highly sensitive to US healthcare policies and pricing dynamics in the generics industry.
Consumer Behavior
Shift toward chronic care, which now accounts for approximately 60% of domestic formulation revenues.
Geopolitical Risks
Exposed to global macroeconomic environments and trade barriers in regulated markets like the US and EU.
Regulatory & Governance
Industry Regulations
Subject to USFDA inspections and EU regulatory standards. Compliance with the Code of Business Conduct and Ethics is affirmed by the Board.
Environmental Compliance
Not disclosed in INR; however, the company focuses on solvent recovery and energy conservation as part of its manufacturing process.
Taxation Policy Impact
Not disclosed as a specific percentage; however, PAT was INR 137.52 Cr on a consolidated basis for FY2025.
Legal Contingencies
The company is obligated to pay a penalty of 11.87 million Euro (plus interest) levied by the EU. Additionally, a $3 million payment is pending for the Bayshore acquisition.
Risk Analysis
Key Uncertainties
Regulatory risks associated with USFDA scrutiny and potential pricing caps in international markets could impact margins by 5-10% if adverse actions occur.
Geographic Concentration Risk
High concentration in the US market, which accounts for 64% of total sales revenue.
Third Party Dependencies
Low dependency on third-party API suppliers due to captive manufacturing, but high dependency on US distributors.
Technology Obsolescence Risk
The company manages technology risk through continuous R&D investment and upgrading manufacturing facilities like the Ghaziabad plant.
Credit & Counterparty Risk
Receivables quality is linked to export markets; high working capital (60% of OI) reflects the extended credit periods typical of international trade.